Soligenix Profile

USD 0.1  6.1%

Acquisition by Joseph Warusz of 600000 shares of Soligenix subject to Rule 16b-3

Soligenix insider trading alert for grant of stock option (right to buy) by Joseph Warusz, VP of Admin Controller, on September 19, 2018. This event was filed by Soligenix Inc with SEC on 2011-12-02. Statement of changes in beneficial ownership - SEC Form 4. Joseph Warusz is currently serves as acting cfo, vice president - finance, corporate secretary of Soligenix [view details]   

Soligenix Summary

Soligenix (SNGX) is traded on Nasdaq Capital Markets in USA. It is located in 29 Emmons Drive and employs 18 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 26.35 M. Soligenix conducts business under Healthcare sector and is part of Biotechnology industry. This company has 17.68 M outstanding shares of which 302.34 K shares are at this time shorted by private and institutional investors with about 1.66 trading days to cover. SOLIGENIX currently holds about 4.24 M in cash with (7.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24.
Check Soligenix Probability Of Bankruptcy

Ownership Allocation (%)

Soligenix Target Price Odds Analysis

Odds Below 1.54HorizonTargetOdds Above 1.54
65.00%30 days 1.54 34.77%
Based on normal probability distribution, the odds of Soligenix to move above current price in 30 days from now is about 34.77% (This Soligenix probability density function shows the probability of Soligenix Stock to fall within a particular range of prices over 30 days) .

Soligenix Top Holders

Soligenix Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Knoll Capital Management LpCommon Shares837.8 K813 K
Vanguard Group IncCommon Shares231.9 K225 K
Cvi Holdings LlcWarrants61 K17 K
View Soligenix Diagnostics

Soligenix Risk Profiles

Soligenix Key Fundamentals

Soligenix Against Markets

Soligenix Current Ratings

Soligenix 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Soligenix are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey. Soligenix operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 18 people. more
Chairman, CEO and PresChristopher SchaberView All
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock View All
Business Address29 Emmons Drive
ExchangeNasdaq Capital Markets
Phone609 538 8200
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestJuly 31, 2018

Soligenix Directors

Soligenix Corporate Directors

Jerome Zeldis Independent Director
Marco Brughera Director
Gregg Lapointe Independent Director
Also please take a look at World Market Map. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.